Eris Lifesciences Limited has informed the Exchange regarding a press release dated August 26, 2025, titled "Eris Lifesciences Receives ANVISA approval for Sterile Injectable Facility".
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences' sterile injectable manufacturing facility in Ahmedabad, operated through its subsidiary Swiss Parenterals (acquired in 2024), has received approval from ANVISA, Brazil's national health regulator. This follows a successful inspection conducted in April 2025, and the company expects approval for a second facility soon. Both facilities are already EU-GMP and PIC/s approved and already supply products to Latin American markets including Mexico, Chile, Argentina, and Peru. The ANVISA approval now allows Eris to launch products in Brazil, giving it comprehensive coverage of the Latin American pharma market. Management called this a step forward in its strategic transformation toward complex injectables and biotechnology, backed by ~INR 4,000 crore of investments over the last 3 years. FY25 revenue stood at INR 2,894 crore.
Positive for the stock — opens access to the large Brazilian pharmaceutical market, strengthens the Latin American export business, and validates the Swiss Parenterals acquisition. Near-term financial impact is not quantified, but it supports the company's long-term growth narrative in complex injectables and biotech.